What is SLXN (SLXN) stock price today?

SLXN (SLXN) is currently trading at $1.95, up 3.72% today.

What is SLXN P/E ratio?

SLXN's P/E ratio is -0.06. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SLXN return on equity (ROE)?

SLXN's return on equity (ROE) is -400.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is SLXN's market cap?

SLXN has a market capitalization of $817042.

NASDAQ · Biotechnology

SLXN (SLXN) Stock

$1.95 +3.72% NASDAQ: SLXN Healthcare

Valuation

Metric	Value
Price	$1.95
Market Cap	$817042
P/E Ratio	-0.06
P/B Ratio	0.10
P/S Ratio	0.00
EPS (TTM)	$-8.96
52-Week High	$223.60
52-Week Low	$1.95
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-400.00%
ROA	-171.43%
ROCE	600.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	1.50
Current Ratio	2.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-1.0M	$-4.0M	$-5.0M	$-13.0M	$12.0M
Net Profit	$-1.0M	$-3.0M	$-5.0M	$-16.0M	$-12.0M
EPS	$-0.05	$0.03	$-4.42	$-2.64	$-8.96
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$115.0M	$9.0M	$5.0M	$3.0M	$7.0M
Total Liabilities	$1.0M	$16.0M	$17.0M	$7.0M	$5.0M
Cash	$0	$8.0M	$5.0M	$1.0M	$6.0M
Borrowings	$0	$0	$0	$4.0M	$0

Latest News

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer GlobeNewswire · Jun 23, 2026 Silexion Therapeutics to Attend BIO International Convention 2026 GlobeNewswire · Jun 16, 2026 Silexion Therapeutics Announces 1-for-10 Reverse Share Split GlobeNewswire · May 26, 2026 Top Premarket Gainers MT Newswires · May 20, 2026 Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-1.0M	$-3.0M	$-5.0M	$-8.0M	$-11.0M
Investing Cash Flow	$0	$-1.0M	$1.0M	$0	$0
Financing Cash Flow	$-3.0M	$0	$0	$2.0M	$0
Net Cash Flow	$0	$-2.0M	$-4.0M	$-3.0M	$5.0M
Free Cash Flow	$-1.0M	$-3.0M	$-5.0M	$-8.0M	$-11.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	-0.48
FCF Yield	-4042.75%
Quick Ratio	1.00
Interest Coverage	—
Return 1Y	-97.74%
Return 3Y	-99.84%
Return 5Y	-99.82%

Ownership

Insiders Held24.16%

Institutions Held1.79%

Institutions Float Held2.36%

Institutional Holder	Shares	Report Date
Pflug Koory, LLC	33	2026-06-30

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AZTR	$0.14	+0.80%	-0.09	$1.49M	0.00%
ENVB	$1.34	+3.88%	-0.04	$799996	0.00%
INDP	$1.39	-3.82%	-0.06	$2.43M	0.00%
JSPR	$0.63	+1.48%	-0.21	$10.24M	0.00%
LIPOLipella Pharmaceuticals Inc.	$0.07	+0.00%	-0.05	$300354	0.00%

About SLXN

SLXN is led by CEO Ilan Hadar, employs 11 people, headquartered in IL, publicly traded since 2024.

SLXN stock trades at $1.95 with a market capitalization of $817042. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.10, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.95 and $223.60, and currently trades 99.1% below its 52-week high.

On profitability, SLXN generates a return on equity (ROE) of -400.00%, return on capital employed of 600.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides